John, seems to be better news for VPHM a 600 mil market cap outfit. There's quite a bit of news out and about on this one, seems to be 3 or 4 outfits targeting neuraminidase inhibitors that battle the flu(including the heavily advertized Relenza) along with WLA's Agouron's division and Pleconaril that appear to target rhinovirus infection as well as other documented viral infections.
How do you figure this is benificial for Zicam. From a longer range view, ie next cold season this might even be harmful.
Mad2
Copyright 2000 Information Access Company,
a Thomson Corporation Company;
IAC (SM) Newsletter Database (TM)
Copyright 2000 Charles W. Henderson
Tuberculosis & Airborne Disease Weekly
January 11, 2000
SECTION: Pg. NA
IAC-ACC-NO: 58558109
LENGTH: 537 words
HEADLINE: Antibiotic and Antiviral Compounds To Be Featured.
AUTHOR-ABSTRACT:
THIS IS THE FULL TEXT: COPYRIGHT 2000 Charles W. Henderson Subscription: $ 995.00 per year. Published weekly. P.O. Box 830409, Birmingham, AL 35283-0409.
BODY:
2000 JAN 11 - (NewsRx.com) -- Late-stage antibacterial compounds in clinic will be featured at the Fifth International Antibacterial Drug Discovery & Development Summit, to be held on March 13-14, 2000, in Princeton, New Jersey, announced the conference sponsor Strategic Research Institute.
A conference on the newest advances by the pharmaceutical industry in developing novel drugs to fight viral diseases, including respiratory/influenza, HIV, and hepatitis B and C, will follow on March 15-16.
The international conference will feature promising antibacterial clinical agents including oxazolidinones, glycylcyclines, beta-lactamases, carbapenems, quinolones, ketolides, everinomycins, and lipopeptides.
Also featured in the broader agenda will be novel antibacterial discovery approaches such as efflux pumps, genomic targets, pharmacokinetic/pharmacodynamic modeling, glycopeptides, and beta-lactamase inhibitors.
Resistance to antibiotic chemotherapies, particularly surveillance efforts to benchmark the growing problem, and papers on Streptococcus pneumoniae and Staphylococcus aureus resistance detected in quinolones, ketolides, and macrolides will be discussed.
Presenters from the pharmaceutical industry include the RW Johnson PRI, Wyeth Ayerst, Hoechst Marion Roussel, Abbott Labs, Schering Plough, Intrabiotics, Cubist, Bristol-Myers Squibb, Pharmacia & Upjohn, Pfizer, Merck, SmithKline Beecham, and Microcide, among others.
The keynote address will be presented by Dr. George Drusano of the Albany Medical College, the organizers announced. The address is entitled "Pharmacokinetic/Pharmacodynamic Alternatives in Antimicrobial Clinical Trials.
The antiviral conference on March 15-16, 2000, will feature new flu compounds targeting neuraminidase inhibitors to be presented by Roche (Tamiflu), Glaxo Wellcome (Relenza), and RW Johnson PRI (RWJ-270201); Agouron's protease inhibitor for rhinovirus infection; and clinical summary of ViroPharma's Pleconaril, a novel therapy for picornaviral disease, will also be featured.
In HIV, the conferences will focus on Trimeris' fusion inhibitor, T-20 and Merck's Integrase inhibitor. Also featured will be new work on reverse transcriptase inhibitors (BioChem Pharma and DuPont), plus contribution from Glaxo Wellcome on resistance testing as a guide to antiretroviral discovery and development in light of the recent U.S. Food and Drug Administration (FDA) Advisory Committee meeting.
The HBV/HCV section will feature discussion of Schering Plough's Ribavirin, Roche's Pegainterferon alfa-2a, and contributions from Eli Lilly and Glaxo Wellcome; Emory University and Novirio Pharmaceuticals will present new data on nucleoside analogs and L-nucleosides, both having shown potent activity against hepatitis B.
For additional information on either conference, to request the agenda, and/or register, contact Camille Coward of Strategic Research Institute at e-mail <ccoward@srinstitute.com>, or by telephone at 1-212-967-0095, x255.
This article was prepared by Tuberculosis & Communicable Disease Weekly editors from staff and other reports. Copyright 2000, Tuberculosis & Communicable Disease Weekly via NewsRx.com.
LANGUAGE: ENGLISH
IAC-CREATE-DATE: January 13, 2000
LOAD-DATE: January 14, 2000
|
